Patents by Inventor Xiao DANG

Xiao DANG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Cell selection method and user equipment
    Patent number: 12256325
    Abstract: A cell selection method and user equipment (UE) are provided. The cell selection method is applied to the UE. The cell selection method includes the steps of obtaining a candidate cell group; selecting a first candidate cell sub-group from the candidate cell group according to the communication ability supported by each candidate cell of the candidate cell group; and selecting a camping cell of the UE from the first candidate cell sub-group.
    Type: Grant
    Filed: September 30, 2021
    Date of Patent: March 18, 2025
    Assignee: MEDIATEK SINGAPORE PTE. LTD.
    Inventors: Hongwei Zhang, Xiaochi Zhao, Xiao Dang, Quanping Wang, Tsung-Ming Lee
  • CELL SELECTION METHOD AND USER EQUIPMENT
    Publication number: 20220022111
    Abstract: A cell selection method and user equipment (UE) are provided. The cell selection method is applied to the UE. The cell selection method includes the steps of obtaining a candidate cell group; selecting a first candidate cell sub-group from the candidate cell group according to the communication ability supported by each candidate cell of the candidate cell group; and selecting a camping cell of the UE from the first candidate cell sub-group.
    Type: Application
    Filed: September 30, 2021
    Publication date: January 20, 2022
    Inventors: Hongwei ZHANG, Xiaochi ZHAO, Xiao DANG, Quanping WANG, Tsung-Ming LEE
  • Cell selection method and user equipment
    Patent number: 11153794
    Abstract: A cell selection method and user equipment (UE) are provided. The cell selection method is applied to the UE. The cell selection method includes the steps of obtaining a candidate cell group; selecting a first candidate cell sub-group from the candidate cell group according to the communication ability supported by each candidate cell of the candidate cell group; and selecting a camping cell of the UE from the first candidate cell sub-group.
    Type: Grant
    Filed: July 2, 2019
    Date of Patent: October 19, 2021
    Assignee: MEDIATEK SINGAPORE PTE. LTD.
    Inventors: Hongwei Zhang, Xiaochi Zhao, Xiao Dang, Quanping Wang, Tsung-Ming Lee
  • CELL SELECTION METHOD AND USER EQUIPMENT
    Publication number: 20200008116
    Abstract: A cell selection method and user equipment (UE) are provided. The cell selection method is applied to the UE. The cell selection method includes the steps of obtaining a candidate cell group; selecting a first candidate cell sub-group from the candidate cell group according to the communication ability supported by each candidate cell of the candidate cell group; and selecting a camping cell of the UE from the first candidate cell sub-group.
    Type: Application
    Filed: July 2, 2019
    Publication date: January 2, 2020
    Inventors: Hongwei ZHANG, Xiaochi ZHAO, Xiao DANG, Quanping WANG, Tsung-Ming LEE
  • Targeted binding agents directed to PDGRF-alpha and uses thereof
    Patent number: 8697664
    Abstract: Targeted binding agents directed to the antigen PDGFR-alpha and uses of such agents are disclosed herein. More specifically the invention relates to fully human monoclonal antibodies directed to the antigen PDGFR-alpha and uses of these antibodies. Aspects of the invention also relate to hybridomas or other cell lines expressing such antibodies. The described targeted binding agents and antibodies are useful as diagnostics and for the treatment of diseases associated with the activity and/or overexpression of PDGFR-alpha.
    Type: Grant
    Filed: February 18, 2010
    Date of Patent: April 15, 2014
    Assignee: MedImmune Limited
    Inventors: Naomi Laing, Jaspal Singh Kang, Ian Foltz, Gadi Gazit-Bornstein, Xiao-Dang Yang, Sue A. Cartlidge, David Charles Blakey
  • TARGETED BINDING AGENTS DIRECTED TO PDGRF-ALPHA AND USES THEREOF
    Publication number: 20110020360
    Abstract: Targeted binding agents directed to the antigen PDGFR-alpha and uses of such agents are disclosed herein. More specifically the invention relates to fully human monoclonal antibodies directed to the antigen PDGFR-alpha and uses of these antibodies. Aspects of the invention also relate to hybridomas or other cell lines expressing such antibodies. The described targeted binding agents and antibodies are useful as diagnostics and for the treatment of diseases associated with the activity and/or overexpression of PDGFR-alpha.
    Type: Application
    Filed: February 18, 2010
    Publication date: January 27, 2011
    Applicant: ASTRAZENECA AB
    Inventors: NAOMI LAING, JASPAL SINGH KANG, IAN FOLTZ, GADI GAZIT-BOMSTEIN, XIAO-DANG YANG, SUE A. CARTLIDGE, DAVID CHARLES BLAKEY
  • Targeted binding agents directed to PDGFR-alpha and uses thereof
    Patent number: 7754859
    Abstract: Targeted binding agents directed to the antigen PDGFR-alpha and uses of such agents are disclosed herein. More specifically the invention relates to fully human monoclonal antibodies directed to the antigen PDGFR-alpha and uses of these antibodies. Aspects of the invention also relate to hybridomas or other cell lines expressing such antibodies. The described targeted binding agents and antibodies are useful as diagnostics and for the treatment of diseases associated with the activity and/or overexpression of PDGFR-alpha.
    Type: Grant
    Filed: August 3, 2007
    Date of Patent: July 13, 2010
    Assignee: AstraZeneca AB
    Inventors: Naomi Laing, Jaspal Singh Kang, Ian Foltz, Gadi Gazit-Bornstein, Xiao-Dang Yang, David Charles Blakey, Sue A. Cartlidge
  • TARGETED BINDING AGENTS DIRECTED TO PDGFR-ALPHA AND USES THEREOF
    Publication number: 20080089837
    Abstract: Targeted binding agents directed to the antigen PDGFR-alpha and uses of such agents are disclosed herein. More specifically the invention relates to fully human monoclonal antibodies directed to the antigen PDGFR-alpha and uses of these antibodies. Aspects of the invention also relate to hybridomas or other cell lines expressing such antibodies. The described targeted binding agents and antibodies are useful as diagnostics and for the treatment of diseases associated with the activity and/or overexpression of PDGFR-alpha.
    Type: Application
    Filed: August 3, 2007
    Publication date: April 17, 2008
    Inventors: Naomi LAING, Jaspal Kang, Ian Foltz, Gadi Gazit-Bornstein, Xiao-Dang Yang, David Blakey, Sue Cartlidge